Keyphrases
Simple Technique
83%
Economic Burden
83%
Clinical Benefit
83%
Factor Importance
83%
Sorafenib
83%
B-cell non-Hodgkin Lymphoma (B-NHL)
83%
Castration-resistant Prostate Cancer
83%
Chemotherapy Failure
83%
Hemophilia A Carrier
83%
Overcoming Resistance
83%
Monoclonal Antibody
83%
Overall Survival
83%
Pounding
83%
Factor VIII Level
83%
Super-elderly
83%
Diagnostic Errors
83%
Young Adult Women
83%
Abnormal Uterine Bleeding
83%
Bleeding Disorders
83%
Factor VIII (FVIII)
69%
Number-needed-to-treat
66%
Elderly Patients
55%
American Colleges
55%
Gynecologist
55%
Obstetricians
55%
Patient Demographics
55%
Oncohematology
50%
X Chromosome Inactivation
41%
Peripartum
41%
Bleeding Symptoms
41%
Incremental Cost
33%
Cost Index
33%
Chemotherapy
27%
Treatment Paradigms
27%
Lymphoma Patients
27%
Bleeding Tendency
27%
Underreported
27%
Young Patients
27%
Current Treatment
27%
Lymphoma
27%
Treatment Decisions
27%
Time to Progression
27%
Current Guidelines
27%
Improved Outcomes
27%
Hematologist
27%
Far-reaching Effect
27%
Early Diagnosis
27%
Screening Diagnosis
27%
Hemophilia
27%
Von Willebrand Disease
27%
Medicine and Dentistry
Haemophilia A
100%
Overall Survival
92%
Bleeding
88%
Monoclonal Antibody
83%
Sorafenib
83%
Health Care Cost
83%
Castration Resistant Prostate Cancer
83%
Blood Clotting Factor 8
83%
Diagnosis
83%
Bleeding Disorder
83%
Numbers Needed to Treat
55%
Menorrhagia
50%
X Chromosome Inactivation
41%
Oncology
41%
Population
33%
Bleeding Diathesis
27%
Hematology
27%
Prostate Specific Antigen
27%
Diseases
23%
Hand Foot Syndrome
18%
Early Diagnosis
16%
Connective Tissue Disease
16%
Patient Population
16%
Blood Stasis
16%
Von Willebrand Disease
16%
Haemophilia B
16%
Counseling
16%
Ehlers Danlos Syndrome
16%
Health Care
13%
Cost-Effectiveness Analysis
13%
Clinical Management
13%
Drug Efficacy
13%
Hemostat
13%
Prevalence
13%
Public Health
13%
Cancer Therapy
13%
Progression Free Survival
13%
Drug Dose Reduction
9%
Gleason Score
9%
Programmed Cell Death
9%
Disease Exacerbation
9%
Solid Malignant Neoplasm
9%
Bone Disease
9%
Docetaxel
9%
Mitoxantrone
9%